Forced diuresis with matched hydration in reducing acute kidney injury during transcatheter aortic valve implantation (Reduce-AKI): study protocol for a randomized sham-controlled trial
- Yaron Arbel†1,
- Eyal Ben-Assa†1Email author,
- Amir Halkin1,
- Gad Keren1,
- Arie Lorin Schwartz1,
- Ofer Havakuk1,
- Eran Leshem-Rubinow1,
- Maayan Konigstein1,
- Arie Steinvil1,
- Yigal Abramowitz1,
- Ariel Finkelstein1 and
- Shmuel Banai1
© Arbel et al.; licensee BioMed Central Ltd. 2014
Received: 11 November 2013
Accepted: 19 June 2014
Published: 2 July 2014
Acute kidney injury (AKI) is observed in up to 41% of patients undergoing transcatheter aortic valve implantation (TAVI) and is associated with increased risk for mortality. The aim of the present study is to evaluate whether furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in patients undergoing TAVI.
Reduce-AKI is a randomized sham-controlled study designed to examine the effect of an automated matched hydration system in the prevention of AKI in patients undergoing TAVI. Patients will be randomized in a 1:1 fashion to the RenalGuard system (active group) versus non-matched saline infusion (sham-controlled group). Both arms receive standard overnight saline infusion and N-acetyl cysteine before the procedure.
The Reduce-AKI trial will investigate whether the use of automated forced diuresis with matched saline infusion is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVI.
Clinicaltrials.gov: NCT01866800, 30 April 30 2013.
Acute kidney injury (AKI) is a frequent complication of coronary angiography, and is associated with unfavorable outcomes including major cardiovascular events, renal replacement therapy, prolonged hospitalization, and early death [1, 2]. Recently, two randomized controlled trials have demonstrated that furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system (PLC Medical Systems, Milford, Massachusetts, USA) [3, 4] reduces AKI in high-risk patients undergoing coronary procedures.
Definition of acute kidney injury post transcatheter aortic valve implantation (TAVI) according to the VARC-2 classification]
Increase in serum creatinine to 150 to 199% of baseline
Increase of ≥0.3 mg/dl (26.4 mmol/L)
Urine output <0.5 ml/kg/h for >6 but <12 h
Increase in serum creatinine to 200 to 299% of baseline
Urine output <0.5 ml/kg/h for >2 but <24 h
Increase in serum creatinine to ≥300% of baseline
Increase of serum creatinine of ≥4 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dl (44 mmol/l)
Urine output <0.3 ml/kg/h for >24 h
Anuria for >12 h
We describe a single-center, double-blinded, randomized sham-controlled trial that is being conducted at the Tel Aviv Medical Center, Tel Aviv, Israel.
Transcatheter aortic valve implantation procedures
All patients will undergo transfemoral aortic valve implantation per standard clinical practice. Briefly, the femoral artery will be accessed with the standard endovascular technique, thereafter the procedure involves advancing a large catheter (18 Fr) through the aortic arch, retrogradely crossing the aortic valve, following by balloon valvuloplasty and stent-valve implantation. During the procedure, the patients will receive analgesics and anxiolytics as per protocol.
Post-procedural pharmacotherapy, sheath removal, and deployment of hemostatic devices will be left to the discretion of the attending cardiologists. Following treatment in the catheterization laboratory, medical treatment throughout hospitalization and follow-up treatment will be left to the discretion of the treating physician managing patient care on the hospital wards. Specific agents added or withdrawn will be made by treating physicians and will not be influenced by the study team.
A total of 220 patients will be randomized. Eligible patients must be planned for elective TAVI and all must have an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2. We limited the number of inclusion and exclusion criteria in order to simulate real-life patients.
subject who is able and willing to give an informed consent is ≥65 years old,
is undergoing planned transfemoral TAVI due to severe aortic stenosis, and
has calculated eGFR below 60 ml/min/1.73 m2 (using Modification of Diet in Renal Disease (MDRD) formula).
history of acute coronary syndrome in the past 30 days,
history of congestive heart failure with left ventricular ejection fraction <30% or exacerbation in the past 30 days,
current dialysis treatment,
known furosemide hypersensitivity, or
contraindications to placement of a Foley catheter in the bladder.
Randomization and blinding
After enrollment, patients will undergo the following baseline procedures: physical examination and medical interview; cardiac echocardiogram assessing systolic and diastolic function, as well as valvular function; endothelial function using the EndoPat™ system, a non-invasive method for assessing endothelial function; carotid artery ultrasound and doppler including Intima Media Thickness calculations; and blood and urine analysis as described below.
All participating patients will receive a standard pre-procedural hydration treatment plan consisting of an infusion of isotonic saline at a rate of 0.5 to 1 mL/kg per hour, starting 12 h prior to the procedure and continuing for 12 h after contrast administration. In addition, 1,200 mg of N-acetyl-cysteine will be administered orally twice daily the day before and the day of the procedure.
Each patient will be randomized to one of the following treatment strategies:
Before the procedure: A standard 18 to 22 gauge catheter will be inserted into a peripheral vein of the arm and a standard Foley catheter will be placed in the bladder for urine collection (as performed routinely for all TAVI procedures). The intravenous (IV) line and the urinary catheter will be connected to the RenalGuard System. The RenalGuard System will be set to 0% match; that is, the urine rate and volume will be measured, but it will not deliver matched IV normal saline. The system will be computed to deliver continues IV normal saline at a rate of 100 cc/h (100 cc/h is the routine average fluid infusion rate in TAVI procedure) during the procedure and up to 6 h after the procedure. Neither a routine IV bolus of saline nor a routine IV furosemide will be given before the procedure.
During the procedure: The urine and infusion volumes will be measured by the RenalGuard system throughout the catheterization procedure and for 6 h after the last contrast dose. Additional IV fluids can be added as needed according to the clinical decision of the anesthesiologist or the attending physician.
We will analyze the quantity and quality of urine during the duration of the procedure.
Group 2 - Active Group (Figure 3B). Treatment as group 1 and in addition, the RenalGuard system will be activated (active mode).
Before the procedure: A standard 18 to 22 gauge catheter will be inserted into a peripheral vein of the arm and a standard Foley catheter will be placed in the bladder for urine collection (as performed routinely for all TAVI procedures). The IV line and the urinary catheter will be connected to the RenalGuard System. The RenalGuard System will be set to 100% match; that is, the urine rate and volume will be measured and the system will deliver volume of IV normal saline that is matched to the volume of urine produced by the patient. An initial IV bolus (250 ml) of normal saline over 30 min will be administered approximately 90 min before the procedure; in patients with heart failure, the volume of the bolus can be reduced to 150 ml. Furosemide will then be administered as a single intravenous bolus of 0.25 to 0.5 mg/kg at the physician’s discretion. When a urine output rate >300 ml/h will be achieved, the patients will be sent to the catheterization laboratory.
During the procedure: Additional doses of furosemide (up to a maximal cumulative dose of 2.0 mg/kg) will be given in cases where the urine output is below 300 ml/h during treatment. Matched hydration will continue throughout the catheterization procedure and for 6 h after the last contrast dose. Additional IV fluids can be added as needed according to the clinical decision of the anesthesiologist or the attending physician. We will analyze the quantity and quality of urine during the duration of the procedure.
Blood and urinary samples
Blood samples will be taken at baseline (on admission); before the procedure; and at 6, 12, 24, 48, and 72 h post-procedure. An 18-gauge cannula will be placed in an antecubital vein for blood sampling. Blood sample analyses will be performed using reagents, calibrators and control materials from Bayer Diagnostics (Berkshire, England) on the ADVIA 1650. At baseline each Patient will provide 40 cc of blood for the following blood tests: full chemistry including lipid levels, thyroid function, BNP, NT-BNP, HbA1c, uric acid, and glucose levels; complete blood count; inflammatory biomarker (hs-CRP, fibrinogen, IL-6, IL-1, MMP, Lp-PLA2, procalcitonin, IL-10, IL-35, TNFa, AchE, and cholinergic status); renal function markers including creatinine, NGAL (neutrophil gelatinase-associated lipocalin), FGF23, and Cystatin-C; and endothelial function markers including I-CAM, V-CAM, superoxide dismutase ADMA, and oxidized LDL. Serum and plasma samples will be frozen for future tests.
Urine samples will be taken at baseline (before the procedure), and after 24 h.
Samples will be taken for basic urinalysis, creatinine, albumin, microalbumin, and electrolytes.
Reduce-AKI is a prospective, randomized, double-blind, sham-controlled clinical trial of the safety and effectiveness of the RenalGuard system in patients with severe aortic stenosis and eGFR <60 ml/min/1.73 m2 undergoing elective TAVI.
The primary endpoint is reduction of acute kidney injury (stage 1 or above) at 48 to 72 h. Serum creatinine level will be measured prior to TAVI and at 48 to 72 h post-procedure. AKI will be defined as stage 1, 2 or 3 according to VARC-2 AKI classification  (Table 1).
The secondary endpoints are to assess whether the RenalGuard system can reduce major adverse clinical events (MACE) defined as a composite of all-cause mortality, myocardial infarction, AKI, 30 day readmission rate, and dialysis. Another secondary endpoint is to assess whether the RenalGuard system can lower 30-day readmission rate and 30-day congestive heart failure exacerbation rate.
Other secondary objectives are to determine whether endothelial function assessment can predict AKI using the EndoPat™ system, to determine whether chronic statins treatment offers any clinical benefit in preventing contrast induced nephropathy, to determine if carotid Doppler analysis can predict AKI occurrence and to determine the predictive value of different biomarkers in assessing the clinical outcome in TAVI patients.
Ethics, informed consent
The study protocol was approved by the Tel Aviv Sourasky Medical Center Institutional Review Board/ Ethics (Helsinki) Committee, approval number: 0111-13-TLV. Oral and written informed consent from the patient will be obtained prior to inclusion.
Flow chart of the anticipated procedures during the study follow-up
1 month ± 7 days
6 months ± 14 days
Full medical history
12 lead ECG†
Adverse events assessment
The RenalGuard system is approved for coronary angiography. Since all patients undergoing TAVI undergo urinary catheterization with a Foley catheter, our major safety issue is related to fluid overload. We will assess this issue by evaluating both in-hospital and 30-day readmission rate for congestive heart failure exacerbation, using patient medical records and medical interviews. In addition, we will evaluate all other safety criteria according to the VARC-2 criteria for TAVI procedures .
An independent DSMB is chartered to monitor and evaluate patient safety to identify any clinically relevant trends, and to recommend whether the study should continue. The DSMB review will occur after 30 randomized patients have completed the 30-day follow-up and after approximately 25%, 50%, and 75% of the cohort has completed their six-month follow-up. An interim analysis for efficacy is planned after 50% of the cohort is enrolled.
The study is powered to detect a 50% reduction in AKI between the groups. The following assumptions and hypotheses correspond to the primary objective:
A = 40% of participants in the sham-controlled group will develop AKI.
B = 20% of participants in the active group will develop AKI.
H0: A = B
H1: A ≠ B
Type I error rate = 5% (2-sided) with power = 80%
Drop out/lost to follow –up, rate = 5%
Under the assumption that AKI is relatively common (40%) after TAVI, and that the RenalGuard system has been shown to reduce the incidence of AKI by up to 70% [3, 4], we estimated that if there will be a 50% reduction in AKI in the RenalGuard group, the number of patients needed in each group to attain 80% power with an alpha of 0.05, is 92. We plan on recruiting 110 patients in each group (220 total) in order to assure achieving statistical power.
Standard statistical analyses will be used to compare the aforementioned endpoints in both study arms. We will compare the incidence of AKI and any clinical differences between the groups. Between-group comparisons of clinical endpoints, biomarkers, and imaging data will be performed using the Mann-Whitney U, independent Student’s t tests, or chi square test according to the distribution of variables. All values will be expressed as medians and interquartile ranges for non-normally distributed continuous variables and as mean and standard error for normally distributed variables.
The statistical analysis of the primary endpoint will performed and presented following the intent-to-treat (ITT) principle. A second set of analysis will be performed using a per-protocol population which will include all enrolled patients who completed the procedure and had a 6-month follow-up. Reported P values will be two-sided, and P <0.05 will be considered as statistically significant. All analyses will be performed using SPSS statistical software.
The Reduce-AKI trial will investigate whether the use of forced diuresis with matched saline infusion using the RenalGuard system will reduce the occurrence of AKI in patients undergoing elective transfemoral TAVI.
AKI following TAVI is an independent predictor of short- and long-term outcome [6, 11] In previously published studies, the incidence of AKI in patients undergoing TAVI ranged from 12% to 41% [6, 9–11] with dialysis required in 1.5 to 10% [6, 16].
The reasons for the increased risk of AKI in patients undergoing TAVI include elder population with multiple comorbidities, peri-procedural bleedings, hemodynamic instability, distal embolization and the use of nephrotoxic drugs.
Hydration is the cornerstone of AKI prevention. It increases the intravascular blood volume, suppresses the renin-angiotensin-aldosterone system, and promotes dilution and rapid evacuation of contrast media [4, 9, 17].
Furosemide may reduce the nephrotoxic effect of contrast media, first by increasing the urine flow and thus diluting the contrast media, and second by blocking tubular sodium reabsorption in the loop of Henle, thus reducing tubular workload and concomitant oxygen requirement.
The use of furosemide alone is controversial since it reduces the effective circulating volume and prostaglandin mediated vasodilation, and may lead to dehydration as a result of increased urine output [18, 19]. However, when combining hydration with furosemide, studies have shown improved outcomes [3, 4].
The RenalGuard system combines all the above methods for prevention of AKI and hydration with forced diuresis with furosemide, while preventing dehydration or fluid overload.
Recently, two randomized controlled trials [3, 4] have demonstrated that furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard system reduces AKI in high-risk patients undergoing coronary procedures by up to 71%. In the present study, we chose to evaluate the effect of the RenalGuard system on patients with reduced eGFR since they are at the highest risk for AKI [6, 7, 20]. In most TAVI patients present with an eGFR below 60 ml/min/1.73 m2, the low eGFR is mostly due to their advanced age (above 80 years). The inclusion/exclusion criteria were very lenient in order to simulate ‘real life’ patients. Therefore, we believe that the Reduce-AKI study will demonstrate a reduction of AKI in this high-risk patient population.
The Reduce-AKI trial has several limitations that need to be discussed. The relatively small sample size will not answer the clinical benefit associated with the RenalGuard system based upon hard cardiovascular events. However, if a reduction of AKI is demonstrated, we feel that it will add valuable information, which might have an effect on the treatment approach to these patients. Second, we will need to conduct a cost-benefit analysis if we find a positive result in order to evaluate its application in clinical practice.
The trial is ongoing. Currently 41 patients have been recruited.
acute kidney injury
clinical event committee
chronic kidney disease
data safety monitoring board
estimated glomerular filtration rate
major adverse clinical events
Modification of Diet in Renal Disease TAVI, transcatheter aortic valve implantation
Valve Academic Research Consortium-2.
Leehee Barak is thanked for administrative and statistical assistance.
This study is supported by internal departmental resources.
- Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL: Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004, 44: 1780-1785. 10.1016/j.jacc.2004.07.043.View ArticlePubMed
- Bartorelli AL, Marenzi G: Contrast-induced nephropathy. J Interv Cardiol. 2008, 21: 74-85. 10.1111/j.1540-8183.2007.00318.x.View ArticlePubMed
- Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G, Investigators RI: Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011, 124: 1260-1269. 10.1161/CIRCULATIONAHA.111.030759.View ArticlePubMed
- Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL: Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012, 5: 90-97. 10.1016/j.jcin.2011.08.017.View ArticlePubMed
- Elhmidi Y, Bleiziffer S, Piazza N, Hutter A, Opitz A, Hettich I, Kornek M, Ruge H, Brockmann G, Mazzitelli D, Lange R: Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation. Am Heart J. 2011, 161: 735-739. 10.1016/j.ahj.2011.01.009.View ArticlePubMed
- Khawaja MZ, Thomas M, Joshi A, Asrress KN, Wilson K, Bolter K, Young CP, Hancock J, Bapat V, Redwood S: The effects of VARC-defined acute kidney injury after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis. Euro Interv. 2012, 8: 563-570.
- Nuis RJ, Van Mieghem NM, Tzikas A, Piazza N, Otten AM, Cheng J, van Domburg RT, Betjes M, Serruys PW, de Jaegere PP: Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2011, 77: 881-889. 10.1002/ccd.22874.View ArticlePubMed
- Podolecka E, Chmielak Z, Demkow M, Michalek P, Ksiezycka-Majczynska E, Chojnowska SL, Hryniewiecki T, Kusmierski K, Juraszynski Z, Czerwinska K, Sitkowska-Rysiak E, Stępińska J, Rużyłło W, Witkowski A: Does contrast agent injection during trans-catheter aortic valve implantation negatively affect kidney function?. Kardiol Pol. 2011, 69: 251-255.PubMed
- Saia F, Ciuca C, Taglieri N, Marrozzini C, Savini C, Bordoni B, Dall’ara G, Moretti C, Pilato E, Martin-Suarez S, Petridis FD, Di Bartolomeo R, Branzi A, Marzocchi A: Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. Int J Cardiol. 2013, 168: 1034-1040. 10.1016/j.ijcard.2012.10.029.View ArticlePubMed
- Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW: Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011, 32: 205-217. 10.1093/eurheartj/ehq406.PubMed CentralView ArticlePubMed
- Genereux P, Kodali SK, Green P, Paradis JM, Daneault B, Rene G, Hueter I, Georges I, Kirtane A, Hahn RT, Smith C, Leon MB, Williams MR: Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria. Am J Cardiol. 2013, 111: 100-105. 10.1016/j.amjcard.2012.08.057.PubMed CentralView ArticlePubMed
- Nuis RJ, Rodes-Cabau J, Sinning JM, van Garsse L, Kefer J, Bosmans J, Dager AE, van Mieghem N, Urena M, Nickenig G, Werner N, Maessen J, Astarci P, Perez S, Benitez LM, Dumont E, van Domburg RT, de Jaegere PP: Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2012, 5: 680-688. 10.1161/CIRCINTERVENTIONS.112.971291.View ArticlePubMed
- Sinning JM, Ghanem A, Steinhauser H, Adenauer V, Hammerstingl C, Nickenig G, Werner N: Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010, 3: 1141-1149. 10.1016/j.jcin.2010.09.009.View ArticlePubMed
- Barbash IM, Ben-Dor I, Dvir D, Maluenda G, Xue Z, Torguson R, Satler LF, Pichard AD, Waksman R: Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. Am Heart J. 2012, 163: 1031-1036. 10.1016/j.ahj.2012.01.009.View ArticlePubMed
- Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB: Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013, 145: 6-23. 10.1016/j.jtcvs.2012.09.002.View ArticlePubMed
- Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, Masson JB, Gutierrez MJ, Clavel MA, Bertrand OF, Pibarot P, Rodés-Cabau J: Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J. 2010, 31: 865-874. 10.1093/eurheartj/ehp552.PubMed CentralView ArticlePubMed
- Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW: Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011, 57: 253-269. 10.1016/j.jacc.2010.12.005.View ArticlePubMed
- Weinstein JM, Heyman S, Brezis M: Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992, 62: 413-415. 10.1159/000187090.View ArticlePubMed
- Solomon R, Werner C, Mann D, D’Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994, 331: 1416-1420. 10.1056/NEJM199411243312104.View ArticlePubMed
- Konigstein M, Ben-Assa E, Abramowitz Y, Steinvil A, Leshem Rubinow E, Havakuk O, Arbel Y, Halkin A, Keren G, Banai S, Finkelstein A: Usefulness of Updated Valve Academic Research Consortiume 2 Criteria for Acute Kidney Injury Following Transcatheter Aortic Valve Implantation. Am J Car. 2013, 112: 1807-1811. 10.1016/j.amjcard.2013.07.048.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.